Hide metadata

dc.date.accessioned2022-04-02T17:23:41Z
dc.date.available2022-04-02T17:23:41Z
dc.date.created2022-01-22T18:35:21Z
dc.date.issued2021
dc.identifier.citationJuraleviciute, Marina Nsengimana, Jérémie Newton-Bishop, Julia Hendriks, Gert J. Slipicevic, Ana . MX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cells to targeted therapy. Cancer Medicine. 2021, 10(8), 2840-2854
dc.identifier.urihttp://hdl.handle.net/10852/93240
dc.description.abstractMX2 is an interferon inducible gene that is mostly known for its antiviral activity. We have previously demonstrated that MX2 is also associated with the tumorigenesis process in melanoma. However, it remains unknown which molecular mechanisms are regulated by MX2 in response to interferon signaling in this disease. Here, we report that MX2 is necessary for the establishment of an interferon-induced transcriptional profile partially through regulation of STAT1 phosphorylation and other interferon-related downstream factors, including proapoptotic tumor suppressor XAF1. MX2 and XAF1 expression tightly correlate in both cultured melanoma cell lines and in patient-derived primary and metastatic tumors, where they also are significantly related with survival. MX2 mediates IFN growth-inhibitory signals in both XAF1 dependent and independent ways and in a cell type and context-dependent manner. Higher MX2 expression renders melanoma cells more sensitive to targeted therapy drugs such as vemurafenib and trametinib; however, this effect is XAF1 independent. In summary, we uncovered a new mechanism in the complex regulation of interferon signaling in melanoma that can influence both survival and response to therapy.
dc.languageEN
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.titleMX2 mediates establishment of interferon response profile, regulates XAF1, and can sensitize melanoma cells to targeted therapy
dc.typeJournal article
dc.creator.authorJuraleviciute, Marina
dc.creator.authorNsengimana, Jérémie
dc.creator.authorNewton-Bishop, Julia
dc.creator.authorHendriks, Gert J.
dc.creator.authorSlipicevic, Ana
cristin.unitcode185,53,18,13
cristin.unitnameAvdeling for patologi
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1
dc.identifier.cristin1987918
dc.identifier.bibliographiccitationinfo:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Cancer Medicine&rft.volume=10&rft.spage=2840&rft.date=2021
dc.identifier.jtitleCancer Medicine
dc.identifier.volume10
dc.identifier.issue8
dc.identifier.startpage2840
dc.identifier.endpage2854
dc.identifier.doihttps://doi.org/10.1002/cam4.3846
dc.identifier.urnURN:NBN:no-95808
dc.type.documentTidsskriftartikkel
dc.type.peerreviewedPeer reviewed
dc.source.issn2045-7634
dc.identifier.fulltextFulltext https://www.duo.uio.no/bitstream/handle/10852/93240/1/Postnr%2B1987918_Juraleviciute%2Bet%2Bal_Cancer%2BMedicine%2B2021_MX2%2Bmediates%2Bestablishment%2Bof%2Binterferon%2Bresponse%2Bprofile%2B%2Bregulates%2BXAF1%2B%2Band%2Bcan.pdf
dc.type.versionPublishedVersion
dc.relation.projectEC/H2020/641458


Files in this item

Appears in the following Collection

Hide metadata

Attribution 4.0 International
This item's license is: Attribution 4.0 International